Your Roundup Case Is Not Automatically Over — But the Strategy Just Changed
You heard the headlines. The Supreme Court ruled for Monsanto. And now you are sitting at a kitchen table at 2 a.m., wondering whether the case you have been thinking about — the one connecting the weedkiller you sprayed for years to the cancer you are now fighting — is dead before it starts.
Here is the direct answer: No. Your case is not automatically over. But it changed, and the legal strategy has to change with it.
The Supreme Court held that federal pesticide law preempts one specific type of claim — the claim that Monsanto failed to warn about cancer risk on the Roundup label. That was the dominant plaintiff theory. It is now largely closed. But the Court did not say Roundup is safe. It did not say glyphosate does not cause cancer. It did not dismiss every legal theory available to people who used Roundup and later developed non-Hodgkin lymphoma. Other claims — design defect, negligent testing, fraudulent concealment — may survive, depending on your exposure history, your diagnosis, and the law of your state.
What the Court decided was a question about federal power, not a question about science. The Environmental Protection Agency has not required a cancer warning on Roundup labels. Under the Federal Insecticide, Fungicide, and Rodenticide Act — FIFRA — the Court ruled that states cannot impose their own labeling requirements through tort law when the federal regulator has not required the warning. That is a preemption ruling. It is a significant defense victory. It is not a scientific finding.
We are going to walk through exactly what the Court held, which claims survived, what your case may be worth now, what evidence you need to preserve, and what to do next. This page is legal information, not legal advice — every case turns on its own facts, and the law varies by state. But by the time you finish reading, you will understand the post-ruling landscape well enough to know whether your case can still proceed and what an experienced toxic tort lawyer should be looking for.
What the Supreme Court Actually Decided in Monsanto v. Durnell
The case was Monsanto Company v. Durnell, and the question before the Court was narrow but consequential: Does FIFRA — the federal statute that governs pesticide registration and labeling — expressly preempt state-law failure-to-warn claims when the EPA has not required a cancer warning on the product label?
The Court answered yes.
FIFRA’s express preemption provision — prohibiting states from imposing labeling requirements in addition to or different from those required under the federal scheme — bars state-law failure-to-warn claims that would effectively mandate cancer warnings the EPA has not required.
Here is what that means in plain English. FIFRA gives the EPA authority over pesticide labels. The EPA has reviewed glyphosate — the active ingredient in Roundup — and classified it as “not likely to be carcinogenic to humans.” Because the EPA did not require a cancer warning on the Roundup label, the Supreme Court held that a state tort law cannot effectively require one either. A jury verdict that says “Monsanto should have warned about cancer on the label” would impose a labeling requirement different from what the EPA approved — and FIFRA says states cannot do that.
This is express preemption. It is not a case-by-case defense. It is a federal statutory command that sweeps away an entire category of state-law claims nationwide. Every federal district court and every state court hearing a Roundup failure-to-warn claim is bound by this ruling.
The practical effect is immediate: if your Roundup case was built primarily on the theory that Monsanto failed to warn about cancer risk on the label, that theory is now preempted. A court will dismiss it. That does not mean every claim in your case is dismissed — it means that specific claim is.
What the Court did NOT decide is just as important. The ruling did not address whether non-warning claims — design defect, negligent testing, fraudulent concealment — are also preempted. The Court left that question for the lower courts. That is the opening through which surviving Roundup cases must now pass.
The Claims That Survived: Design Defect, Negligent Testing, Corporate Misconduct
The Supreme Court closed the failure-to-warn door. It did not close every door. Three categories of claims potentially survive the preemption ruling because they do not depend on what the label says or what the EPA required on the label.
Design defect is the theory that Roundup is unreasonably dangerous by its very design — that the product itself, regardless of any warning, is defective because the risks of glyphosate formulation outweigh its utility and a safer alternative design existed. This claim does not ask the jury to impose a labeling requirement. It asks the jury to evaluate the product’s design. Whether it survives preemption depends on the specific state’s product liability framework and how the claim is pleaded. Some courts may hold that a design defect claim implicitly demands a label warning and is therefore preempted; others may allow it if it is built on the product’s formulation rather than its labeling. This is an unsettled question that will be litigated case by case.
Negligent testing and research misconduct is the theory that Monsanto failed to adequately study glyphosate’s carcinogenic potential — or worse, manipulated the scientific literature and regulatory submissions to downplay the risk. This claim is about what Monsanto did or did not do in the laboratory and in the regulatory process, not about what the label says. Allegations that Monsanto ghostwrote scientific papers, influenced regulatory determinations, or suppressed unfavorable studies support this theory. It may survive preemption because it targets corporate conduct independent of labeling obligations. But it faces significant general-causation challenges — the defense will argue that the EPA’s regulatory position undermines the plaintiff’s scientific case regardless of how the research was conducted.
Fraudulent concealment is the theory that Monsanto intentionally suppressed or distorted evidence of carcinogenic risk. This is a fraud claim, not a labeling claim. It requires proof that Monsanto had specific knowledge of the risk and actively concealed it. It is discovery-intensive and fact-dependent — you have to find the internal documents that show what the company knew and when it knew it. Substantial volumes of corporate documents have already been produced in the Roundup multidistrict litigation, and those productions may contain the evidence a fraudulent concealment claim needs. This claim may survive preemption because it is independent of labeling duties, but it requires a high proof threshold and a fact pattern that shows deliberate concealment, not just disagreement about the science.
Each of these surviving theories faces a common challenge: the EPA’s classification of glyphosate as “not likely to be carcinogenic to humans” creates a powerful defense narrative. The defense will use it in Daubert motions to challenge the admissibility of plaintiff causation experts, arguing that the experts’ opinions contradict the federal regulatory determination. Plaintiff epidemiological and toxicological experts must bridge the gap between the IARC hazard classification and specific-causation opinions through dose-response modeling and exposure reconstruction. This is the make-or-break battleground for surviving Roundup claims — if your experts are excluded, your case cannot reach a jury regardless of which legal theory you pursue.
The EPA Versus IARC: Why the Court’s Ruling Is Not a Safety Finding
One of the most confusing aspects of the Supreme Court’s ruling is that it appears to answer the scientific question — does Roundup cause cancer? — when it actually answers a legal question about who gets to decide what goes on a pesticide label.
The confusion comes from a genuine divergence between two respected scientific bodies that reached different conclusions about glyphosate, using different methodologies.
The Environmental Protection Agency classified glyphosate as “not likely to be carcinogenic to humans.” This is a risk-based regulatory determination — it considers the likelihood of harm under real-world exposure conditions, including dose, route, and duration. The EPA’s review incorporates registrant-submitted studies and regulatory toxicology data. It is the determination that underpins the preemption analysis: because the EPA did not require a cancer warning, states cannot impose one.
The International Agency for Research on Cancer — a subsidiary of the World Health Organization — classified glyphosate as “probably carcinogenic to humans,” placing it in Group 2A. This is a hazard-based classification — it identifies whether a substance has the potential to cause cancer, without weighing real-world exposure levels. IARC’s methodology focuses on the intrinsic properties of the agent, not the probability that any specific person will be harmed under typical use conditions.
These are not contradictory findings. They are answers to different questions. The EPA asked: “Under realistic exposure conditions, is glyphosate likely to cause cancer in humans?” IARC asked: “Does glyphosate have properties that can cause cancer?” A substance can be a probable carcinogen by hazard identification and still be judged unlikely to cause cancer at the doses people actually encounter. The two assessments use different frameworks, different data sets, and different standards of evidence.
The Supreme Court’s preemption ruling rests on the EPA’s regulatory determination, not on a scientific finding that glyphosate is safe. The Court did not evaluate the scientific evidence. It did not weigh the EPA assessment against the IARC classification. It did not decide whether glyphosate causes non-Hodgkin lymphoma. It decided that FIFRA gives the EPA authority over pesticide labels and that state tort law cannot override that authority.
This distinction matters enormously for surviving Roundup claims. The EPA-IARC divergence is not a closed question — it is a live scientific debate that will continue to shape expert-admissibility battles in every non-preempted Roundup case. Plaintiff experts can rely on the IARC classification as part of their general-causation framework, but they must go further: they must provide dose-response opinions, exposure reconstructions, and specific-causation analyses that connect the plaintiff’s individual Roundup exposure to their specific cancer diagnosis.
The defense will argue that the EPA’s determination should control. The plaintiff will argue that IARC’s hazard identification, combined with epidemiological evidence and exposure-specific dose reconstruction, supports causation. The jury — if the case gets past Daubert — will decide which scientific narrative is more persuasive. That fight is unchanged by the Supreme Court’s preemption ruling.
Monsanto and Bayer: Who You Are Really Up Against
The company that designed, manufactured, marketed, and distributed Roundup is Monsanto Company. But Monsanto has not been an independent company since 2018, when Bayer AG — the German pharmaceutical and chemical giant — acquired it for approximately $63 billion. Bayer assumed the totality of Roundup litigation exposure and settlement responsibilities as part of that acquisition.
The corporate structure matters because it determines who you sue, who holds the money, and who controls the defense strategy. Monsanto Company operates as a subsidiary of Bayer AG. In the Roundup multidistrict litigation — MDL-2741, centralized in the Northern District of California before Judge Vince Chhabria — Monsanto is the named defendant, but Bayer is the entity that has allocated billions in reserves for Roundup claims and directs the global settlement and defense strategy.
Bayer is a balance-sheet defendant. It is one of the largest pharmaceutical and chemical companies in the world, with resources that dwarf any individual plaintiff. The company has already committed substantial sums to settling Roundup claims — billions of dollars across multiple settlement frameworks — and it now benefits from a narrowed liability landscape after the Supreme Court’s ruling. The failure-to-warn theory that drove the largest verdicts is preempted, which reduces Bayer’s aggregate exposure and gives the company leverage to offer less in settlement negotiations.
But Bayer’s resources also mean that if a surviving claim succeeds — if a design defect, negligent testing, or fraudulent concealment claim reaches a jury and wins — the defendant has the resources to pay a significant verdict. There is no insurance ceiling problem here. The question is not whether the money exists; it is whether your case can get to a jury on a non-preempted theory with admissible expert testimony.
The Roundup MDL docket reflects the scale of this litigation. As of mid-2026, approximately 3,909 actions were pending in the consolidated federal proceeding, with additional cases filed in state courts across the country. Several bellwether trials produced headline verdicts before the preemption question reached the Supreme Court. Those earlier verdicts — some reaching eight and nine figures — relied heavily on failure-to-warn theories that are now preempted. Post-ruling verdicts, if they come, will be built on different theories and may look different in dollar terms.
If your loved one died from non-Hodgkin lymphoma after significant Roundup exposure, the wrongful death claim follows the same legal landscape. The failure-to-warn theory is preempted for wrongful death claims just as it is for personal injury claims. But design defect, negligent testing, and fraudulent concealment theories may survive in a wrongful death context, and survival actions may recover the decedent’s conscious pain and suffering and medical expenses between diagnosis and death. The specific damages available and the procedural requirements for bringing a wrongful death claim vary by state — the beneficiary class, the damages split between the estate and surviving family, and any tort-reform caps are all state-specific questions that must be confirmed for your jurisdiction.
What a Roundup Case Is Worth After the Ruling
The Supreme Court’s ruling has changed the settlement and verdict landscape for Roundup cases. Being honest about that change is the only way to give you a useful valuation framework.
Before the ruling, Roundup verdicts reached eight and nine figures. Those verdicts were built primarily on failure-to-warn theories — the theory that Monsanto knew about the cancer risk and failed to warn consumers on the label. That theory is now preempted. Cases that relied entirely or primarily on failure-to-warn have lost their primary legal engine, and their settlement value has dropped substantially as a result.
After the ruling, case value depends on four variables:
The surviving claim quality. A case with strong design defect evidence — expert testimony on alternative formulations, risk-utility analysis, and consumer expectations — carries more value than a case with only a generic “the product is dangerous” assertion. A case with corporate misconduct evidence — internal documents showing suppressed research, ghostwritten studies, or regulatory manipulation — carries more value because it supports both liability and punitive damages. A case with only a weak negligent testing theory, unsupported by specific documentary evidence, carries less.
Expert admissibility outcomes. If your causation experts survive Daubert challenges — if the court allows them to testify that glyphosate can cause non-Hodgkin lymphoma and that it caused yours — your case can reach a jury. If they are excluded, your case cannot proceed regardless of the legal theory. The EPA’s regulatory position gives the defense a powerful argument for exclusion, and the plaintiff’s experts must be prepared to distinguish their methodology from the EPA’s risk assessment. Expert selection is the single most important strategic decision in a post-ruling Roundup case.
Jurisdiction. State product liability frameworks vary significantly. Some states apply a consumer-expectations test for design defect; others apply a risk-utility test requiring proof of a reasonable alternative design. Some states cap non-economic or punitive damages. Some states have favorable tort law for plaintiffs; others have aggressive tort-reform statutes. The same case can be worth materially more or less depending on where it is filed. Forum selection — where your case can properly be filed — is a strategic decision that experienced counsel must make early.
Punitive damages posture. Punitive damages have been a significant feature in prior Roundup verdicts, driven by allegations that Monsanto manipulated scientific research and regulatory processes. But the preemption ruling may indirectly weaken the predicate for punitives tied specifically to failure-to-warn conduct. Plaintiff counsel must anchor punitives in non-warning corporate misconduct — research manipulation, suppression of unfavorable data, ghostwriting of scientific literature — rather than in the failure to put a cancer warning on the label.
With those variables in mind, the valuation range after the ruling is roughly as follows: cases that cannot be retooled onto a surviving theory are worth zero. Cases with strong non-preempted claims, favorable jurisdiction, admissible experts, and punitive-damage exposure based on corporate misconduct evidence may be worth several million dollars or more. The dossier suggests a range of $5 million to $15 million or higher for well-built non-preempted claims with strong specific-causation proof — but every case is different, and these figures are illustrative, not predictive.
Settlement leverage has diminished. Bayer perceives a narrowed plaintiff claim portfolio and will adjust settlement expectations downward. Maintaining pressure requires strong design defect predicates, demonstrable corporate misconduct evidence, and selection of favorable jurisdictions. Mediation should be approached with realistic post-ruling valuation — overstating case value based on pre-ruling verdicts will damage credibility and weaken the negotiating position.
Past results depend on the facts of each case and do not guarantee future outcomes.
Non-Hodgkin Lymphoma: The Injury and Its Proof
Non-Hodgkin lymphoma is a cancer of the lymphatic system — specifically of lymphocytes, the white blood cells that help the body fight infection. It is one of the most common cancers in the United States, and it is the diagnosis that most Roundup plaintiffs share.
The disease begins when a lymphocyte undergoes a malignant transformation, multiplying abnormally and accumulating in lymph nodes, spleen, bone marrow, or other lymphoid tissue. There are more than 70 subtypes of non-Hodgkin lymphoma, classified by the type of lymphocyte affected (B-cell or T-cell) and the growth pattern (indolent or aggressive). Diffuse large B-cell lymphoma is the most common subtype alleged in Roundup litigation — an aggressive B-cell lymphoma that typically requires immediate treatment.
Diagnosis begins with a biopsy of an enlarged lymph node or affected tissue. The pathology report confirms the diagnosis and identifies the subtype through immunophenotyping — flow cytometry or immunohistochemistry that characterizes the malignant cells. Staging follows: imaging studies (PET/CT) to determine how widely the disease has spread, bone marrow biopsy to check for marrow involvement, and blood tests to assess organ function and tumor markers. The histological subtype, stage at diagnosis, and molecular markers all determine treatment and prognosis.
Treatment depends on subtype and stage but typically involves some combination of chemotherapy (R-CHOP is the standard regimen for diffuse large B-cell lymphoma — rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), radiation therapy for localized disease, immunotherapy, and — for relapsed or refractory cases — stem cell transplants or CAR-T cell therapy. Treatment is grueling. R-CHOP cycles run every two to three weeks for six cycles, each cycle carrying risks of infection, cardiac toxicity, nerve damage, and bone marrow suppression. Stem cell transplants involve high-dose chemotherapy that destroys the patient’s own marrow, followed by reinfusion of stem cells — weeks of hospitalization, severe immunosuppression, and a long recovery. CAR-T therapy, the newest option for refractory cases, costs hundreds of thousands of dollars and carries risks of cytokine release syndrome and neurotoxicity.
The proof problem the defense exploits is that non-Hodgkin lymphoma has many known causes and risk factors that have nothing to do with glyphosate. Immunosuppression (from HIV, organ transplant medications, or autoimmune conditions), certain viral infections (Epstein-Barr, HTLV-1, HCV), a family history of lymphoma, and chemical exposures other than glyphosate are all recognized risk factors. Many cases of non-Hodgkin lymphoma are classified as idiopathic — no identifiable cause. The defense argues that the plaintiff’s cancer was idiopathic or caused by something other than Roundup. The plaintiff’s expert must provide a specific-causation opinion: that this plaintiff’s exposure to glyphosate, at this dose, over this duration, was a substantial factor in causing this plaintiff’s specific subtype of non-Hodgkin lymphoma. That opinion must rest on general-causation evidence (glyphosate can cause NHL), dose-response analysis (how much this plaintiff was exposed to), and differential diagnosis (ruling out other known causes).
Lifetime costs are substantial. Induction chemotherapy alone can cost tens of thousands to over $100,000. Stem cell transplants can cost $200,000 to $500,000 or more. CAR-T therapy is priced at approximately $375,000 or more per treatment, before hospitalization costs. Ongoing surveillance — regular imaging, blood work, and specialist visits — continues for years, sometimes for life. Lost wages during treatment and recovery, diminished earning capacity, and the psychological cost of living with a cancer diagnosis that may relapse are all part of the damages picture. A life-care planner builds the cost stream; a forensic economist reduces it to present value. These are the numbers that a real demand is built from — not guesses, not averages from other cases, but the specific costs this plaintiff faces.
The Evidence Clock: What Exists and How Fast It Disappears
Every toxic tort case is a race against evidence decay. The Supreme Court’s ruling does not change that race — the same records that prove your exposure and your diagnosis are still out there, and they are still degrading. Here is what exists, who holds it, and how fast it can legally disappear.
Your exposure history and usage documentation is the foundation of your specific-causation case. This includes purchase receipts for Roundup products, work records showing occupational use (for agricultural workers, landscapers, groundskeepers, and maintenance staff), product containers with labels identifying the specific formulation and concentration, and sworn statements from family members, coworkers, or employers who can verify the frequency, duration, and amount of your Roundup use. This evidence degrades over years — memories fade, receipts are discarded, coworkers move or pass away, and employers go out of business. Obtain sworn statements and gather purchase records promptly. Do not assume you will remember the details accurately in two years.
Your medical records, pathology reports, and treatment history confirm your cancer diagnosis, histological subtype, staging, treatment protocol, response, remission or relapse status, and prognosis. These records are stable in institutional medical files — hospitals and oncology practices maintain records for years under state retention requirements. But you should obtain complete copies immediately, not just for the lawsuit but for your own understanding of your treatment history. The pathology report is particularly critical — it contains the exact subtype diagnosis that your specific-causation expert will rely on.
Monsanto and Bayer internal corporate documents may reveal knowledge of carcinogenic risk, ghostwriting of scientific literature, regulatory manipulation, or suppression of unfavorable studies. These documents support surviving negligent testing, fraud, and punitive damages theories. Substantial volumes have already been produced in MDL discovery, and access may be possible through prior productions or targeted discovery in non-preempted claims. But additional custodial collections become harder as the litigation winds down and the urgency of document preservation decreases. The MDL’s document depository may remain accessible, but the window for obtaining new, previously unproduced documents is narrowing.
EPA registration files and regulatory correspondence demonstrate the regulatory framework underlying the preemption ruling and may reveal agency findings, Monsanto submissions, or internal EPA deliberations relevant to non-warning claims. These are public records, stable and accessible through Freedom of Information Act requests, but navigating them efficiently requires regulatory-litigation experience.
The IARC monograph and peer-reviewed epidemiological literature establish the general-causation framework for plaintiff expert testimony and anchor the scientific case independent of the EPA regulatory determination. The published scientific record is stable but continuously evolving — new studies emerge that may strengthen or weaken the causal inference. Monitor the literature for publications that affect your expert’s opinions and the defense’s Daubert arguments.
The preservation letter — the formal demand that the defendant and any third parties freeze relevant documents, data, and physical evidence — should go out the day you retain counsel. The longer you wait, the more evidence degrades. In a post-ruling Roundup case, the preservation letter should specifically demand retention of internal research documents, regulatory submission files, scientific publication drafts and communications, and any documents related to glyphosate’s carcinogenic potential — the evidence that supports surviving negligent testing and fraudulent concealment claims.
Monsanto’s Defense Playbook — and How to Counter Each Move
The Supreme Court’s ruling gives Monsanto and Bayer a new set of tools. Here are the plays they will run and the counters that experienced toxic tort counsel should deploy.
Play 1: “Your case is over.” The day after the ruling, Monsanto’s lawyers and claims representatives will tell plaintiffs and their counsel that the Supreme Court killed the Roundup litigation. They will send letters offering small settlement amounts, framed as a courtesy, before the plaintiff has had time to evaluate surviving theories. The counter: the ruling preempted one theory — failure to warn. It did not address design defect, negligent testing, or fraudulent concealment. A case built on a surviving theory is still viable. Do not accept a settlement offer based on the premise that your entire case is dead. Get an independent evaluation of which theories fit your facts.
Play 2: Low settlement offers citing reduced leverage. Bayer will use the ruling to argue that its aggregate exposure has decreased and that settlement values should be adjusted downward. They will point to the preempted failure-to-warn theory as the engine that drove prior large verdicts and argue that without it, cases are worth a fraction of their pre-ruling value. The counter: maintain pressure through strong design defect predicates, demonstrable corporate misconduct evidence for punitives, and selection of jurisdictions with favorable product liability frameworks and no aggressive tort reform caps. A well-built non-preempted claim in the right jurisdiction still carries significant value. The ruling reduced leverage; it did not eliminate it.
Play 3: Daubert motions using the EPA’s position. The defense will file motions to exclude plaintiff causation experts, arguing that the experts’ opinions contradict the EPA’s regulatory determination that glyphosate is “not likely to be carcinogenic.” They will frame the EPA’s classification as the federal scientific consensus and the plaintiff’s experts as outliers who contradict it. The counter: plaintiff experts must be prepared to explain the methodological difference between the EPA’s risk-based assessment and IARC’s hazard-based classification, to present epidemiological evidence supporting the causal inference, and to provide dose-response specific-causation opinions grounded in the plaintiff’s actual exposure history. The EPA’s regulatory determination is not a scientific finding that glyphosate is safe — it is a risk-based policy judgment, and a qualified expert can distinguish it from a hazard identification without contradicting it dishonestly.
Play 4: “You waited too long.” The defense will argue that the statute of limitations has run, particularly for plaintiffs who learned of their diagnosis years ago but only recently connected it to Roundup exposure. The counter: toxic tort cases typically apply a discovery rule — the clock starts when the plaintiff knew or reasonably should have known of the injury and its connection to the exposure, not when the exposure occurred. The date of that discovery is a fact-specific question. But this is also why waiting is dangerous — the longer you delay, the harder it becomes to argue that you did not know or should not have known.
Play 5: Pressuring quick settlements before plaintiffs retool. Bayer knows that retooling a case from failure-to-warn to design defect or negligent testing takes time, expert work, and documentary development. They will push for quick settlements at reduced values before plaintiffs can build their surviving theories. The counter: do not let the defense set your timeline. Your case is worth what it is worth on its best theory, not what it is worth in the first 30 days after a ruling. Take the time to build the non-preempted claims properly.
How a Surviving Roundup Case Is Actually Built
Here is the chronological walk of how a post-ruling Roundup case is constructed, from the first call through resolution.
Week one: intake and theory selection. The first conversation is not about filing a lawsuit — it is about determining whether a surviving theory fits your facts. What was your exposure? How long did you use Roundup? How frequently? What concentration? Was it occupational or residential? What is your exact NHL subtype? When were you diagnosed? What does your pathology report say? What other risk factors do you have? These facts determine which surviving theory — design defect, negligent testing, fraudulent concealment — is the strongest fit for your case. If the only theory that fits your facts is failure to warn, the ruling may bar your case. If the facts support a non-labeling theory, the case can proceed.
Weeks one through four: preservation and records collection. The preservation letter goes out to Monsanto and any third parties who hold relevant evidence. Medical records are obtained and organized. Exposure documentation is assembled — purchase records, work history, usage affidavits from people who can verify your Roundup use. The goal is to lock down the factual foundation before memories fade and documents disappear.
Months one through three: expert selection and case theory development. This is the make-or-break phase. Plaintiff causation experts — typically an epidemiologist, a toxicologist, and possibly an oncologist or hematologist — must be selected and retained. Their opinions must be developed: general causation (glyphosate can cause NHL), dose-response (the plaintiff’s exposure level is sufficient to cause NHL), and specific causation (glyphosate caused this plaintiff’s NHL, not something else). The defense will challenge these opinions in Daubert motions, so the expert reports must be methodologically rigorous and prepared to withstand scrutiny.
Months three through six: discovery and corporate document review. In a non-preempted claim, discovery targets the corporate misconduct evidence that supports negligent testing and fraudulent concealment theories. Internal research documents, regulatory submission files, communications between Monsanto and the EPA, ghostwriting allegations, and suppression of unfavorable studies are the documentary spine of the surviving claims. Much of this material has already been produced in the MDL, but targeted discovery in individual cases may yield additional documents.
Months six through twelve: Daubert motions and dispositive motions. The defense will file Daubert motions to exclude plaintiff experts, using the EPA’s regulatory position as the core argument. The plaintiff must defend the experts’ methodology, distinguish the EPA risk assessment from IARC hazard identification, and present the epidemiological and toxicological basis for the causation opinions. If the experts are excluded, the case cannot proceed. If they survive, the case moves toward trial.
Year one and beyond: trial or settlement. If the case survives Daubert and dispositive motions, it proceeds to trial on the surviving theories or enters serious settlement negotiations. Post-ruling settlements will be lower than pre-ruling settlements for comparable cases, but a well-built non-preempted claim with strong corporate misconduct evidence and admissible experts still carries meaningful value.
Your Deadline to Sue Has Not Changed
The Supreme Court’s ruling changes the legal theories available to Roundup plaintiffs. It does not change the deadline to file a lawsuit.
Toxic tort cases — including Roundup non-Hodgkin lymphoma claims — are subject to statutes of limitations that vary by state. Most states impose a deadline of between two and six years for personal injury claims. Wrongful death claims carry their own deadlines, typically shorter, running from the date of death rather than the date of injury.
The critical question for toxic tort cases is when the clock starts. Most states apply a discovery rule: the statute of limitations begins to run when the plaintiff knew or reasonably should have known of the injury and its connection to the exposure. For a Roundup plaintiff, that typically means the clock starts around the time of diagnosis — when you learned you had non-Hodgkin lymphoma — or when you first learned that Roundup exposure may have caused your cancer, whichever is later under your state’s rule.
The Supreme Court’s ruling does not restart or pause the statute of limitations. If your clock was running before the ruling, it is still running. If your deadline has passed, the ruling does not reopen it. If your deadline has not yet passed, the ruling does not extend it.
Some states also impose a statute of repose — an outer deadline that can bar a claim after a set period regardless of when the injury was discovered. Repose statutes are particularly dangerous in toxic tort cases because the disease may not manifest until long after the exposure. Whether a statute of repose applies to your claim, and whether it bars your case, is a state-specific question that must be confirmed for your jurisdiction.
The practical message is this: the ruling may have narrowed your legal options, but your deadline is the same as it was the day before the ruling was issued. If you have been waiting to see how the Supreme Court would rule before calling a lawyer, the ruling is in, and the clock is still running. An experienced attorney must evaluate which surviving theories fit your specific facts before the filing deadline in your state expires.
What to Do in the First 72 Hours
If you used Roundup and were diagnosed with non-Hodgkin lymphoma, and you are now wondering whether the Supreme Court’s ruling affects your ability to pursue a claim, here is what to do — and what not to do — in the immediate aftermath.
Do get your medical records organized. Request complete copies from your oncologist and treating hospital: the pathology report that confirmed your diagnosis, your treatment records, imaging studies, and your current treatment plan. These documents are the medical foundation of any case, and they are easiest to obtain while you are an active patient.
Do document your Roundup exposure in writing. Write down everything you can remember: what products you used (Roundup concentrate, ready-to-use, Roundup Pro, or other formulations), where you purchased them, how often you used them (daily, weekly, seasonally), how many years you used them, whether you mixed concentrates (which involves higher exposure), whether you used protective equipment, and whether your exposure was occupational or residential. Do this now — memory degrades, and the details you write down today will be more accurate than the details you try to recall in two years.
Do get sworn statements from people who can verify your usage. Family members who saw you spray Roundup in the yard. Coworkers who worked alongside you applying herbicide. Employers whose records show you worked in a position involving herbicide application. These statements lock in testimony while memories are fresh.
Do not sign anything from Monsanto, Bayer, or their representatives. If you receive a letter offering a settlement, a release, or a waiver — from the company, from their insurance carrier, from their claims administrator — do not sign it. These documents are designed to close your case cheaply before you have had time to evaluate your options with independent counsel. Any document you sign may be binding and may waive rights you do not yet know you have.
Do not give a recorded statement. If a claims representative calls to “check on you” or asks you to “just tell us what happened” on a recording, decline. Recorded statements are engineered to elicit statements that can be used against you — minimizing your exposure, expressing uncertainty about your diagnosis, or acknowledging factors that the defense can later use to argue your cancer had another cause.
Do not post about your case on social media. The defense monitors social media. Posts about your health, your activities, your treatment, or your legal plans can be taken out of context and used to minimize your injuries or contradict your testimony. Assume everything you post is being read by someone whose job is to find ammunition against your claim.
Do call experienced toxic tort counsel. The day you call is the day the preservation letter goes out, the day your exposure history begins to be documented under legal supervision, and the day your case theory begins to be evaluated by someone who knows the difference between a preempted failure-to-warn claim and a surviving design defect claim. The call costs nothing. The consultation is free. And if we cannot help you, we will tell you that honestly.
Frequently Asked Questions
Is my Roundup case over because of the Supreme Court ruling?
Not automatically. The ruling preempted failure-to-warn claims — the theory that Monsanto should have put a cancer warning on the Roundup label. Other theories — design defect, negligent testing, fraudulent concealment — may survive because they do not depend on the label. Whether your case can proceed depends on whether your facts support a surviving theory. An experienced toxic tort attorney can evaluate that.
What did the Supreme Court actually decide?
The Court held that FIFRA — the federal pesticide law — preempts state-law failure-to-warn claims when the EPA has not required a cancer warning on the product label. The ruling is about federal regulatory authority over pesticide labeling, not about whether glyphosate causes cancer. The Court did not evaluate the scientific evidence or make a safety finding.
Does the ruling mean Roundup is safe?
No. The ruling is a legal preemption decision, not a scientific safety determination. The EPA has classified glyphosate as “not likely to be carcinogenic to humans,” while the International Agency for Research on Cancer classified it as “probably carcinogenic to humans” (Group 2A). This scientific divergence remains a live question that will continue to shape expert testimony in surviving Roundup cases.
Can I still sue if I already filed a failure-to-warn claim?
If your existing case is built solely on failure to warn, the defense will likely move to dismiss that claim on preemption grounds. However, you may be able to amend your complaint to add surviving theories — design defect, negligent testing, fraudulent concealment — if the facts support them and the statute of limitations has not run. Whether amendment is possible depends on your jurisdiction’s procedural rules and the timing of your case. Speak to your attorney immediately about retooling your claims.
How long do I have to file a Roundup lawsuit?
The deadline varies by state, typically between two and six years for personal injury claims. Toxic tort cases usually apply a discovery rule — the clock starts when you knew or should have known of your injury and its connection to Roundup exposure. The Supreme Court ruling does not change the deadline. If your clock was running before the ruling, it is still running now. Some states also have statutes of repose that can bar claims after an outer period regardless of discovery. Confirm the specific deadline for your state with an attorney.
What if my loved one died from non-Hodgkin lymphoma after using Roundup?
A wrongful death claim follows the same legal landscape as a personal injury claim. The failure-to-warn theory is preempted, but design defect, negligent testing, and fraudulent concealment theories may survive. Wrongful death damages — funeral expenses, loss of financial support, loss of consortium — and survival damages — the decedent’s conscious pain and suffering and medical expenses between diagnosis and death — may be recoverable. The specific damages available and the procedural requirements vary by state. The statute of limitations for wrongful death is typically shorter than for personal injury and runs from the date of death.
Will the ruling affect existing settlements?
Settlements that have already been finalized and approved are generally binding and are not reopened by a subsequent judicial ruling. However, the ruling may affect pending settlement negotiations and cases that were in the process of being resolved when the decision came down. If you are in active settlement negotiations, the ruling may change the leverage dynamics. Do not accept a settlement offer without having it evaluated by independent counsel who understands the post-ruling landscape.
What evidence do I need for a surviving Roundup claim?
You need the same evidence any Roundup case requires — exposure documentation, medical records confirming your NHL diagnosis, and pathology reports — plus additional evidence specific to the surviving theory. For design defect: expert testimony on alternative formulations and risk-utility analysis. For negligent testing: corporate documents showing inadequate research or manipulated studies. For fraudulent concealment: internal documents showing Monsanto knew of the risk and suppressed it. Much of the corporate document evidence may already exist in MDL productions.
How much is my Roundup case worth now?
Case value depends on the surviving claim quality, expert admissibility outcomes, jurisdiction, and punitive damages posture. Cases that cannot be retooled onto a surviving theory may be worth nothing. Well-built non-preempted claims with strong causation proof, favorable jurisdiction, and corporate misconduct evidence may be worth several million dollars or more. Pre-ruling verdicts that relied on failure-to-warn are not reliable indicators of post-ruling value. An honest valuation requires a case-specific evaluation by experienced counsel.
Should I accept a settlement offer from Monsanto or Bayer?
Not without independent legal evaluation. Settlement offers made in the immediate aftermath of the ruling are likely to be low, designed to close cases quickly before plaintiffs can evaluate and build surviving theories. The ruling reduced settlement leverage, but it did not eliminate the value of well-built non-preempted claims. Before accepting any offer, have it evaluated by an attorney who understands which theories survived and what your case is worth on those theories.
Why People Call Attorney911
Attorney911 is The Manginello Law Firm, PLLC — a Houston-based trial firm that has spent more than two decades fighting for people injured by corporate products and corporate decisions. We are not the counsel of record on this Supreme Court case or on any specific Roundup matter you may have read about. But we are a powerful resource for the education, the governing law, the evidence clocks, and the honest evaluation of what a case like yours is worth in the post-ruling landscape.
Ralph Manginello is our managing partner — 27 years in courtrooms, including federal court, a journalist before he was a lawyer, and a competitor who hates losing. He built this firm on the principle that the people who get hurt by corporate products deserve the same quality of legal firepower as the corporations that made them. Ralph speaks Spanish.
Lupe Peña is our associate attorney — a former insurance-defense attorney who spent years inside a national defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue claims exactly like yours. He sat on the other side of the table. He knows how the machine works from the inside. Now he uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full consultations without an interpreter.
We work on contingency. That means we do not get paid unless we win your case. The fee is 33.33% before trial and 40% if the case goes to trial. Your first consultation is free, and it is confidential. You will speak with a live person, 24 hours a day, 7 days a week — not an answering service.
If you used Roundup and were diagnosed with non-Hodgkin lymphoma, the Supreme Court ruling changed the legal landscape — but it did not close every door. The question is whether your facts fit through one of the doors that remains open. That question can only be answered by an experienced toxic tort attorney who reviews your exposure history, your medical records, and the specific law of your state.
Call us at 1-888-ATTY-911 — that is 1-888-288-9911. The call is free. The consultation is free. And if we are not the right fit for your case, we will tell you that honestly and point you toward someone who is.
Hablamos Español.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Every case turns on its own facts, and the law varies by state. Nothing on this page creates an attorney-client relationship. If you are considering a Roundup claim, speak with an attorney in your jurisdiction before the filing deadline expires.